.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,122,917

« Back to Dashboard
Patent 8,122,917 protects VARITHENA and is included in one NDA.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 8,122,917

Title:Apparatus and method for dispensing foam
Abstract: A foam transfer device is described, for use with aerosol canister apparatus for producing a sclerosant foam for the treatment of, inter alia, varicose veins. The device enables diversion of an initial quantity of below-specification foam from the canister to waste, e.g. to an integral waste chamber, before dispensing a further quantity of foam for use in treatment. The switching of the flow from the waste chamber to a different outlet for use is accomplished without interrupting the flow from the aerosol canister since this would cause the foam to drop below specification again. The waste chamber may be transparent so that the foam entering it can be observed and a decision made by a user when to stop diverting foam to waste. Alternatively, the foam may be diverted automatically e.g. when a set time has elapsed or a set volume of foam dispensed. The foam for use is normally dispensed into a syringe for subsequent injection into a varicose vein of a patient.
Inventor(s): Harman; Anthony David (Oxon, GB), Wright; David Dakin Iowerth (High Waycombe, GB), Mijers; Jam Wilem Marinus (Haarlem, NL), Kay; Stuart Brian William (Cambridge, GB), Hurlstone; Christopher John (Cambridge, GB), Dixon; Julina Richard (Cambridge, GB), Pocock; Andrew Gordon (Cambridge, GB), Hogan; Brendan (Co Galway, IE)
Assignee: BTG International Limited (London, GB)
Application Number:12/923,209
Patent Claim Types:
see list of patent claims
Device;
Patent Metrics:
Source: PatentQuant.com
Field: Handling
Back Citations: 28th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYes8,122,917► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,122,917

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0321210.7Sep 10, 2003

Non-Orange Book Patents for Patent: 8,122,917

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,814,943Apparatus and method for dispensing foam► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,122,917

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria486023► subscribe
Australia2004270475► subscribe
BrazilPI0414281► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc